July 2, 2012
Astellas Pharma announced on June 29 that the US FDA has approved its overactive bladder (OAB) treatment mirabegron for OAB associated with urge urinary incontinence and urgency, and urinary frequency. Under the brand name of Myrbetriq, the drug is scheduled...read more